Abstract
The validity of Next Generation Sequencing (NGS) technologies to identify genetic, genomic and transcriptional heterogeneity in clinical cancer samples raises the potential of individualized breast cancer treatment. Although this research strategy has already provided exiting findings many challenges remain to translate NGS-based outcomes into clinical precision oncology for breast cancer. Static and spatiotemporal genome and transcriptome analysis have already identified new cancer genes, novel oncotargets as well as the development of dynamic intratumor heterogeneity and serial circulating cell-free DNA as predictive biomarkers to guide optimal individualized therapy. Emerging clinic-genomic trials are required to validate this promising data.
(Citation: Gastric & Breast Cancer 2019; 14(1): 56-72)
|
